指南与共识血栓与止血

ISTH SSC 指南:普通肝素的监测与管理(第一部分)

How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH.
指南 / 共识 · J Thromb Haemost · 2026-05-20

国际血栓与止血学会(ISTH)通过德尔菲流程制定共识指南,规范普通肝素(UFH)分析前、分析和临床管理。推荐抗Xa活性监测优于活化部分凝血活酶时间,目标抗Xa水平0.30–0.70 U/mL,按体重给药,不常规补充抗凝血酶。

要点

  • 抗Xa活性监测优于APTT,目标0.30–0.70 U/mL。
  • 采血后1小时内离心,离心后10分钟内检测。
  • 推荐按体重给药方案,不常规补充抗凝血酶。

核心结论

  • 抗Xa活性是UFH监测的首选方法,目标水平0.30–0.70 U/mL适用于多数适应症。

研究设计与样本

  • ISTH基于调查发现的实践异质性,通过德尔菲流程制定共识指南。

主要发现

  • 实践调查显示UFH管理存在显著异质性,促使制定循证指导。
  • 抗Xa试验受干扰少且无需确定本地范围,优于APTT。

关键数值与推荐

  • 采血后1小时内离心,离心后10分钟内检测,1小时间隔可接受。
  • 推荐标准3.2%(109 mM)缓冲枸橼酸钠管,不常规使用CTAD管。
  • 抗Xa目标水平0.30–0.70 U/mL用于静脉血栓栓塞、动脉事件和机械心脏瓣膜。
  • 若使用APTT,必须建立本地肝素治疗范围。
  • 推荐基于体重的给药列线图,无单一首选列线图。

临床怎么用

  • 优先采用抗Xa试验监测UFH,目标0.30–0.70 U/mL。
  • 按体重列线图调整剂量,避免常规补充抗凝血酶。

局限性

  • 指南指出关键证据缺口,需进一步研究优化UFH监测和给药。
  • 未来文件将涉及特殊人群和围手术期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The International Society on Thrombosis and Haemostasis (ISTH) recently published a survey on the management of unfractionated heparin (UFH), which revealed substantial heterogeneity in practice and highlighted the need to develop evidence-based guidance. This document summarizes evidence and provides consensus guidance, developed through a Delphi process, for preanalytical, analytical, and clinical aspects of UFH management. For preanalytical issues, optimal practice includes centrifuging blood samples within 1 hour of collection and testing within 10 minutes of centrifugation, although a 1-hour interval is acceptable. Standard 3.2% (109 mM) buffered trisodium citrate tubes are recommended, with no routine use of CTAD (citrate, theophylline, adenosine, and dipyridamole) tubes due to cost and uncertain benefit. Analytically, anti-Xa assays are preferred over activated partial thromboplastin time for UFH monitoring, as they are less affected by interferences and do not require the determination of a local range. Assays without dextran sulphate or added antithrombin are optimal, especially to avoid overestimating UFH activity after protamine reversal. Establishing a local heparin therapeutic range is essential if activated partial thromboplastin time is used. Clinically, a target anti-Xa level of 0.30 to 0.70 U/mL is suggested for most indications, including venous thromboembolism, arterial events, and mechanical heart valves. Weight-based nomograms are recommended for dosing, although no single nomogram is preferred due to limited outcome data. Antithrombin supplementation is generally not advised for acquired deficiency. The guidance highlights critical evidence gaps and calls for further research to optimize UFH monitoring and dosing, with future documents addressing special populations and periprocedural management.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Gouin-Thibault I, Frere C, Castellucci LA, et al. How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH. J Thromb Haemost. 2026. PMID: 42162738. doi:10.1016/j.jtha.2026.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。